143 related articles for article (PubMed ID: 34861348)
1. Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
Peek J; Koirala B; Brady SF
Bioorg Med Chem Lett; 2022 Feb; 57():128484. PubMed ID: 34861348
[TBL] [Abstract][Full Text] [Related]
2. Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis.
Mosaei H; Molodtsov V; Kepplinger B; Harbottle J; Moon CW; Jeeves RE; Ceccaroni L; Shin Y; Morton-Laing S; Marrs ECL; Wills C; Clegg W; Yuzenkova Y; Perry JD; Bacon J; Errington J; Allenby NEE; Hall MJ; Murakami KS; Zenkin N
Mol Cell; 2018 Oct; 72(2):263-274.e5. PubMed ID: 30244835
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus.
Robertson GT; Bonventre EJ; Doyle TB; Du Q; Duncan L; Morris TW; Roche ED; Yan D; Lynch AS
Antimicrob Agents Chemother; 2008 Jul; 52(7):2313-23. PubMed ID: 18443108
[TBL] [Abstract][Full Text] [Related]
4. The Enzymes of the Rifamycin Antibiotic Resistome.
Surette MD; Spanogiannopoulos P; Wright GD
Acc Chem Res; 2021 May; 54(9):2065-2075. PubMed ID: 33877820
[TBL] [Abstract][Full Text] [Related]
5. A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin Resistant Pathogens.
Peek J; Xu J; Wang H; Suryavanshi S; Zimmerman M; Russo R; Park S; Perlin DS; Brady SF
ACS Infect Dis; 2020 Sep; 6(9):2431-2440. PubMed ID: 32786275
[TBL] [Abstract][Full Text] [Related]
6. Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Ma Z; Lynch AS
J Med Chem; 2016 Jul; 59(14):6645-57. PubMed ID: 27336583
[TBL] [Abstract][Full Text] [Related]
7. Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of Staphylococcus aureus.
Kerns RJ; Rybak MJ; Kaatz GW; Vaka F; Cha R; Grucz RG; Diwadkar VU; Ward TD
Bioorg Med Chem Lett; 2003 May; 13(10):1745-9. PubMed ID: 12729656
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro antibacterial activity of 7-(3-alkoxyimino-5-amino/methylaminopiperidin-1-yl)fluoroquinolone derivatives.
Zhang Y; Li G; Liu M; You X; Feng L; Lv K; Cao J; Guo H
Bioorg Med Chem Lett; 2011 Feb; 21(3):928-31. PubMed ID: 21232952
[TBL] [Abstract][Full Text] [Related]
9. Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.
Butler MM; Lamarr WA; Foster KA; Barnes MH; Skow DJ; Lyden PT; Kustigian LM; Zhi C; Brown NC; Wright GE; Bowlin TL
Antimicrob Agents Chemother; 2007 Jan; 51(1):119-27. PubMed ID: 17074800
[TBL] [Abstract][Full Text] [Related]
10. Kanglemycin A Can Overcome Rifamycin Resistance Caused by ADP-Ribosylation by Arr Protein.
Harbottle J; Mosaei H; Allenby N; Zenkin N
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0086421. PubMed ID: 34606341
[TBL] [Abstract][Full Text] [Related]
11. Covalently linked kanamycin - Ciprofloxacin hybrid antibiotics as a tool to fight bacterial resistance.
Shavit M; Pokrovskaya V; Belakhov V; Baasov T
Bioorg Med Chem; 2017 Jun; 25(11):2917-2925. PubMed ID: 28343755
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase Inhibitors Addressing Fluoroquinolone Resistance in Gram-Negative Bacteria.
Skepper CK; Armstrong D; Balibar CJ; Bauer D; Bellamacina C; Benton BM; Bussiere D; De Pascale G; De Vicente J; Dean CR; Dhumale B; Fisher LM; Fuller J; Fulsunder M; Holder LM; Hu C; Kantariya B; Lapointe G; Leeds JA; Li X; Lu P; Lvov A; Ma S; Madhavan S; Malekar S; McKenney D; Mergo W; Metzger L; Moser HE; Mutnick D; Noeske J; Osborne C; Patel A; Patel D; Patel T; Prajapati K; Prosen KR; Reck F; Richie DL; Rico A; Sanderson MR; Satasia S; Sawyer WS; Selvarajah J; Shah N; Shanghavi K; Shu W; Thompson KV; Traebert M; Vala A; Vala L; Veselkov DA; Vo J; Wang M; Widya M; Williams SL; Xu Y; Yue Q; Zang R; Zhou B; Rivkin A
J Med Chem; 2020 Jul; 63(14):7773-7816. PubMed ID: 32634310
[TBL] [Abstract][Full Text] [Related]
13. The antibacterial activity of a new 3-azinomethyl-rifamycin.
Strippoli V; Bruzzese T; Galli R; Simonetti N; Tronci N
Farmaco Sci; 1988; 43(7-8):619-25. PubMed ID: 3147199
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, antimicrobial, and DNA gyrase inhibitory properties of fluoroquinolone-dichloroacetic acid hybrids.
Seliem IA; Panda SS; Girgis AS; Nagy YI; George RF; Fayad W; Fawzy NG; Ibrahim TS; Al-Mahmoudy AMM; Sakhuja R; Abdel-Samii ZKM
Chem Biol Drug Des; 2020 Feb; 95(2):248-259. PubMed ID: 31623026
[TBL] [Abstract][Full Text] [Related]
15. A novel bi-functional chalcone inhibits multi-drug resistant Staphylococcus aureus and potentiates the activity of fluoroquinolones.
Gupta VK; Gaur R; Sharma A; Akther J; Saini M; Bhakuni RS; Pathania R
Bioorg Chem; 2019 Mar; 83():214-225. PubMed ID: 30380450
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of novel structural hybrids of benzofuroxan derivatives and fluoroquinolones.
Chugunova E; Akylbekov N; Bulatova A; Gavrilov N; Voloshina A; Kulik N; Zobov V; Dobrynin A; Syakaev V; Burilov A
Eur J Med Chem; 2016 Jun; 116():165-172. PubMed ID: 27061980
[TBL] [Abstract][Full Text] [Related]
17. New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.
Combrink KD; Denton DA; Harran S; Ma Z; Chapo K; Yan D; Bonventre E; Roche ED; Doyle TB; Robertson GT; Lynch AS
Bioorg Med Chem Lett; 2007 Jan; 17(2):522-6. PubMed ID: 17070048
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and antibacterial activity of new fluoroquinolones containing a cis- or trans-cyclohexane moiety.
Qi QR; Pan J; Guo XQ; Weng LL; Liang YF
Bioorg Med Chem Lett; 2012 Dec; 22(24):7688-92. PubMed ID: 23102889
[TBL] [Abstract][Full Text] [Related]
19. Next-generation strategy for treating drug resistant bacteria: Antibiotic hybrids.
Gupta V; Datta P
Indian J Med Res; 2019 Feb; 149(2):97-106. PubMed ID: 31219074
[TBL] [Abstract][Full Text] [Related]
20. New fluoroquinolone compounds with endo-nortropine derivatives at C-7 position show antibacterial activity against fluoroquinolone-resistant strains of Staphylococcus aureus.
Salunke RA; Shukla M; Kaul G; Bansal BR; Chopra S; Chhibber M
Chem Biol Drug Des; 2019 Sep; 94(3):1626-1633. PubMed ID: 30860312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
